XBIO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	2 719.00
Average Volume	6 016.00
Market Cap	5.93M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.790 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.420
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-06	Mizrahy Moshe	Buy	2 500	Stock Options
2023-12-06	Mizrahy Moshe	Sell	0	Common Stock
2023-12-11	Lockshin Curtis	Buy	10 000	Stock Options
2023-12-11	Eisenberg Jeffrey F	Buy	20 000	Stock Options
2023-12-11	Parslow James F	Buy	10 000	Stock Options

INSIDER POWER
100.00
Last 95 transactions
Buy: 3 350 890 \| Sell: 1 809 302

Xenetic Biosciences Inc Correlation

10 Most Positive Correlations
HNNA	0.854
APOP	0.847
MDRR	0.841
MBIO	0.836
YTEN	0.834
ISNS	0.826
NCTY	0.821
JAKK	0.819
PRPO	0.809
SBGI	0.805

10 Most Negative Correlations
BOCH	-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xenetic Biosciences Inc Financials

Annual	2023
Revenue:	$2.54M
Gross Profit:	$2.54M (100.00 %)
EPS:	$-2.71

Q4	2023
Revenue:	$671 963
Gross Profit:	$671 963 (100.00 %)
EPS:	$-0.760

Q3	2023
Revenue:	$611 174
Gross Profit:	$611 174 (100.00 %)
EPS:	$-0.690

Q2	2023
Revenue:	$651 005
Gross Profit:	$651 005 (100.00 %)
EPS:	$-0.690

Financial Reports:

No articles found.

Xenetic Biosciences Inc

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.